Study design: This was a two-part pilot study in men with erectile dysfunction (ED) due to spinal cord injury (SCI: cord level range T6-L5). Part I was a randomised, double-blind, twoway cross-over study comparing a single dose of sildena®l 50 mg or placebo. Part II was a randomised, double-blind, parallel-group evaluation of sildena®l 50 mg or placebo, taken as required (not more than once daily) approximately 1 h prior to sexual activity, over a period of 28 days. Objectives: To assay the ecacy and safety of sildena®l 50 mg and placebo. Setting: Clinic-and home-based assessments in the United Kingdom. Methods: A total of 27 subjects who were able to achieve at least a grade 2 erection (hard, but not hard enough for penetration) in response to penile vibratory stimulation (PVS) were recruited. In Part I, the re¯exogenic response of the penis to PVS was evaluated in the clinic while in Part II, the response to treatment was assessed in the home (global ecacy, questionniare, diary). Results: In Part I, 17/26 (65%) subjects had erections of 460% rigidity at the penile base (median duration 3.5 min) after sildena®l compared with 2/26 (8%) (median duration 0 min) after placebo (P=0.0003). In Part II, 9/12 (75%) subjects on sildena®l and 1/14 (7%) subjects on placebo reported that the treatment had improved their erections (P50.005), and 8/12 (67%) and 2/13 (15%) men, respectively, indicated that they wished to continue treatment (P50.02). An analysis of diary data showed no dierence between the groups with respect to the mean number of erections hard enough for penetration (P=0.08). The mean proportion of attempts at sexual intercourse that were successful was 30 and 15%, respectively (P=0.21). Similarly, responses to the end-of-treatment questionnaire indicated that there were no signi®cant dierences between the groups with respect to the frequency of erections hard enough for sexual intercourse (P=0.47) or that lasted as long as the subject would have liked (P=0.11). No subject discontinued sildena®l due to adverse events. Conclusion: Sildena®l is an eective, well-tolerated oral treatment for ED in SCI subjects. Sponsorship: This study was funded by P®zer Inc.
Introduction
Erectile dysfunction (ED), de®ned by the National Institutes of Health Consensus Panel as the inability to achieve or maintain an erection sucient for satisfactory sexual performance, 1 is a common complication in men with a spinal cord injury (SCI). Approximately 10 000 traumatic SCIs are estimated to occur in the United States each year, with approximately two-thirds of these new cases involving individuals aged 16 ± 30 years, of whom approximately 80% are men. 2 The neurological level and severity of SCIs varies considerably, but in general more than half of all SCI men are unable to achieve erections that permit successful sexual intercourse. 3 Not surprisingly early and maximal attention to optimising the sexual function of men following a SCI has a high positive correlation with the overall success of rehabilitation. 4 Corpus cavernosal smooth muscle relaxation and penile erection are predominately mediated by nitric oxide (NO) via the induction of cyclic guanosine monophosphate (cGMP) in the corpora. 5, 6 It is hypothesised that an agent which acts to amplify the NO/cGMP signal in the corpus cavernosum would increase the intensity and duration of the erectile response to local tactile stimulation (mediated by the sacral re¯ex) in men with SCI.
The orally active drug sildena®l acts peripherally as a selective inhibitor of cGMP-speci®c phosphodiesterase type 5, 7 an important regulator of cGMP in the human corpus cavernosum, and has been reported to signi®cantly enhance the erectile response in ablebodied (non-SCI) men with ED of mixed and psychogenic aetiology. 8 This paper presents the results of a two-part, randomised, double-blind, placebo-controlled study evaluating the ecacy and safety of sildena®l (50 mg) for the treatment of ED in SCI subjects with some residual re¯exogenic erectile capability.
Methods

Study design
This pilot study was conducted at three centres in the United Kingdom. A single triangular sequential trial design 9 (see Appendix I) was used so that subjects were not recruited unnecessarily. The study had two parts ( Figure 1) . Part I had a randomised, double-blind, twoway crossover design and assessed the re¯exogenic erectile response to penile vibratory stimulation (PVS) after single doses of sildena®l or placebo; Part II was a randomised, double-blind, placebo-controlled, parallelgroup evaluation of sildena®l in the home setting.
The protocol was approved by the Ethics Committee at each participating site. All patients in the study gave written informed consent.
Subjects
The entry criteria for the study were males aged 18 ± 55 years, a documented history of SCI (sustained at least 6 months prior to screening), a female partner, ED solely attributable to SCI, and the ability to achieve at least a grade 2 re¯exogenic erectile response (see Assessments and statistical analyses) to PVS (using FertiCare TM vibrators) during screening. Subjects receiving self-injection therapy for their ED were permitted to enter the study provided they met the above criteria and did not continue to use intracavernous injections in the week before screening or during the study. Subjects taking drugs with a recognised potential to be causally associated with ED were also eligible provided that the dose remained unchanged for 1 month before screening and throughout the study.
Subjects with SCIs at or above the T5 level were excluded to eliminate the potential risk of autonomic dysre¯exia during PVS in Part I of the study. Subjects with genital anatomical deformities causing ED, or known or suspected vascular or endocrine causes of ED were also excluded from the study. Further exclusion criteria were known postural hypotension or a resting sitting blood pressure (BP) 580/ 50 mmHg, documented major haematological, renal or hepatic abnormalities, diabetes mellitus, and a history of stroke, subarachnoid haemorrhage, bleeding disorder or active peptic ulceration. Also excluded from entry were subjects receiving nitrates or anticoagulants, men who had taken any experimental drug within the previous 3 months, and subjects who drank more than 28 units of alcohol per week (1 unit=1/2 pint of beer, 0.8 ounce of spirits, or 1 glass of wine). Subjects who were clinically depressed were excluded unless the investigator could ensure that they had the motivation to participate reliably in the study.
Drug treatment
In Part I, men were assigned to receive single doses of sildena®l 50 mg (2625 mg capsules) and matching placebo in a random order, with a washout period of at least 3 days between treatment periods; this was based on the half-life of sildena®l (approximately 4 h). 10 In Part II, subjects were randomised to either sildena®l 50 mg or placebo for 28 days. As the observed time to maximum plasma concentration (T max ) of sildena®l is approximately 60 min, 10 subjects were instructed to take their treatment as needed approximately 1 h prior to sexual activity, but not more than once daily.
Assessments and statistical analyses
In Part I, the duration of erections of 460% and 480% rigidity (an erection 460% rigidity is considered as sucient for penetration 7, 8 ) at the base and tip of the penis in response to PVS were recorded 30, 60 and 90 min after drug dosing using penile plethysmography (RigiScan Plus TM ); the vibrator settings used in both cross-over periods were those which had maximised the re¯exogenic erectile response during screening. Sitting BP and pulse rate measurements were performed throughout penile plethysmography and any subject showing a hypertensive dysre¯exic response was immediately withdrawn from the study. A subjective assessment of the best re¯exogenic erectile response was also recorded by the patient using a ®ve-point qualitative scale (0=no response, 1=increase in size, but not hard, 2=hard, Figure 1 Study design but not hard enough for penetration, 3=hard enough for penetration, but not completely hard, 4=com-pletely hard).
At the end of Part II, subjects were asked two global ecacy questions:`Has the treatment you have been taking recently (over the last 4 weeks) improved your erections?' (Question A) and`If this treatment you have been taking recently were freely available would you want to continue taking it?' (Question B).
Subjects also completed a diary during Part II, recording information on drug dosing, and quality of all erections associated with sexual stimulation, stating hardness and whether erections lasted long enough for satisfactory sexual activity. Subjects also answered an eight-item sexual function questionnaire and their partners were simultaneously asked to complete a two-item questionnaire (for full details of both see Appendix II) at the screening visit and after 28 days of treatment. The responses to both questionnaires were scored using a ®ve-point scale, in which a score of one was the least favourable.
All adverse events that occurred during study treatment or within 7 days of the end of treatment were recorded, regardless of causality, and were graded by severity (mild, moderate, severe). Routine biochemical and haematological safety tests were also performed at the screening visit, during the 28-day treatment period and at a follow-up visit 2 weeks later.
The primary ecacy variable was the response to global ecacy question A. The secondary ecacy variables were the responses to global ecacy question B, the patient sexual function and partner questionnaires, the weekly count of erections sucient to permit intercourse (grades 3 or 4), and the proportion of attempts at sexual intercourse that were successful (de®ned as occasions when the subject took the study drug, had a grade 3 or 4 erection, and stated that the erection lasted long enough for satisfactory sexual activity).
Intent-to-treat (ITT) analyses were performed for all the ecacy variables. The ITT analyses included all randomised subjects who received treatment and had any post-baseline assessments, regardless of any protocol deviations or whether they completed the study. All signi®cance tests were two-sided and tested at the 5% level; details of the speci®c statistical tests used are presented in Appendix I.
Results
Recruitment and demographic characteristics A total of 27 subjects were randomised before recruitment to the study was closed (see Appendix I). The two randomised groups in Part II [sildena®l (13), placebo (14)] were comparable in terms of age, duration of ED and the degree of spinal cord lesion assessed on the criteria of the American Spinal Injury Association (ASIA) Impairment Scale 11 (see Table 1 ). One subject randomised to the sildena®l group was lost to follow-up before completing Part I and is therefore not included in the analysis of results.
The median duration of treatment in both groups during Part II was 33 days, with subjects taking a median of eight doses of either sildena®l or placebo. Overall, 13 subjects (48%) had received previous drug or non-drug treatment(s) for ED. Concomitant medications were taken by 21 subjects during the study, with similar numbers in each of the treatment groups. ED=erectile dysfunction. *American Spinal Injury Association Impairment Scale categories, where A=complete (no sensory or motor function preserved in the sacral segments S4-S5); B=incomplete (partial sensory function but no motor function is preserved below the neurological level and extends through the sacral segments S4-S5); C=incomplete (motor function is partially preserved below the neurological level, and the majority of key muscles below the neurological level have muscle grade 53/5); D=incomplete (motor function is preserved below the neurological level, and the majority of key muscles below the neurological level have muscle grade 53/5); and E=normal (sensory and motor function normal). 11 {One subject was lost to follow-up during Part I of the study. {{One subject was non-evaluable in Part II as there was no evidence that medication had been taken Ecacy In Part I of the study, 17 of the 26 subjects (65%) had erections 460% rigidity at the penile base after sildena®l treatment compared with two (8%) after placebo (P50.01; Figure 2 ). The median duration of the erections achieved was 3.5 and 0.0 min, respectively; the estimated median treatment dierence was 5.5 min [95% con®dence interval (CI) 2.0 ± 15.25; P=0.0003]. A total of nine (35%) subjects had erections 480% rigidity at the base of the penis after sildena®l compared with one (4%) after placebo, and the estimated median dierence between the treatments for the duration of the erection was 0.25 min (95% CI 0 ± 2.25; P=0.01).
For penile tip recordings, 12 men (46%) had erections 460% rigidity on sildena®l, compared with one (4%) after treatment with placebo ( Figure 2) . Corresponding ®gures for penile tip recordings 480% rigidity were six (23%) and none (0%), respectively. The estimated treatment dierences in duration of erections 460% and 480% rigidity were 1.25 min (95% CI 0 ± 5; P=0.0016) and 0 min (95% CI 0 ± 0.75; P=0.0166), respectively.
Data on the mean subjective grade of erection achieved after PVS in Part I is presented in Figure 3 ; the dierence of 1.16 (95% CI 0.69 ± 1.61) in mean grade between sildena®l and placebo was highly signi®cant (P50.0001).
In response to global ecacy question A at the end of Part II of the study, 9/12 (75%) subjects in the sildena®l group and 1/14 (7%) subjects in the placebo group stated that treatment had improved their erections (P50.005) ( Table 2 ). In the sildena®l group, an improvement in erections was reported by all ®ve (100%) of the subjects with incomplete spinal cord lesions (ASIA grade B ± D) and four of the seven subjects (57%) with complete cord lesions (ASIA grade A). In response to global ecacy question B, 67% of the sildena®l group and 15% of the placebo group indicated that they would want to continue treatment if it were available at the end of the study (P50.02; Table 2 ).
The analysis of diary data indicated that the mean number of erections hard enough for penetration was 1.8/week for subjects receiving sildena®l compared with 0.4/week for those receiving placebo (P=0.08). The mean proportion of attempts at sexual intercourse that were successful was 30 and 15%, respectively; this dierence was not statistically signi®cant (P=0.21).
Of the seven questions analyzed from the patient sexual function questionnaire, only the mean response scores for the question assessing satisfaction with sex life (question 7) demonstrated a statistically signi®cant dierence (P=0.01) between treatment groups, with subjects in the sildena®l group being more satis®ed with their sex life ( Table 2) . Although not reaching statistical signi®cance, mean response scores for the questions assessing the frequency and quality of erections (questions 4, 5 and 6) were higher for sildena®l-treated subjects than for those treated with placebo ( Table 2 ). The mean response scores for the two questions on the partner questionnaire were also higher for the sildena®l than the placebo group, although these dierences did not attain statistical signi®cance (Table 2) .
Safety
All 27 subjects were included in the safety analyses and the results are reported in Table 3 . During Part I, when single doses were administered, seven (26%) subjects experienced a total of nine events after sildena®l, and Figure 2 The percentage of subjects with penile rigidity 460% including median duration in minutes as measured by penile plethysmography (Part I) Figure 3 Subject assessment of rigidity of best erection achieved during PVS (Part I) four (15%) subjects reported four events after placebo administration. During Part II, ®ve (42%) men in the sildena®l group and four (31%) men in the placebo group reported six and eight adverse events, respectively. Of the 15 reported events with sildena®l, only four (anxiety and headache in Part I, dyspepsia and a respiratory disorder in Part II) were considered by the blinded investigator to be treatment related. There were no serious events associated with sildena®l, but one subject in the placebo group in Part II was hospitalised due to severe epididymitis and orchitis.
Sildena®l had no eect on the sitting BP or pulse rate during Part I. One subject randomised to the sildena®l group in Part II had a laboratory test abnormality (elevated neutrophil count) during the study, but this was not considered to be treatmentrelated and did not result in study withdrawal.
Discussion
Sildena®l acts to amplify the eects of the NO/cGMP pathway in the penis during sexual stimulation. It should therefore require at least partial integrity of the neural pathway mediating erection in order to exert a therapeutic eect. In men with SCI, sildena®l may increase the erectile response to local tactile stimulation (via the sacral re¯ex) or to psychogenic stimuli depending upon which pathways may still be preserved.
In Part I of this study, sildena®l was shown to signi®cantly improve re¯exogenic erectile responses to PVS. Penile plethysmography showed that 65% of subjects had satisfactory erections of 460% rigidity at the penile base (median duration of 3.5 min) after sildena®l compared with 8% following placebo (median duration 0 min) (P=0.0003). This objective parameter of erectile function agreed well with the reports of grade 3 or 4 erections in the home setting, as some 70% of subjects who had satisfactory erections and no response on placebo also had grade 3 or 4 erections when radomised to receive sildena®l in Part II. These results suggest that for this study population a therapeutic threshold of penile basal rigidity of 460% is a fair and conservative indicator of erections rigid enough for penetration (grade 3 or 4) during sexual intercourse.
Subjects receiving sildena®l during Part II reported that treatment had signi®cantly improved their erections (P50.05) and satisfaction with their sex life (P=0.01). Furthermore, signi®cantly more men in the sildena®l group than in the placebo group (67% vs 15%) wanted to continue treatment at the conclusion of the study (P50.02).
In contrast, the results of other secondary ecacy variables in the sexual function questionnaire, the partner questionnaire and diary data, although favouring sildena®l, failed to attain statistical significance. This lack of signi®cance in these secondary endpoints is a not entirely unexpected consequence of using a sequential analysis technique, which in this study led to early termination of recruitment because of the clear treatment-related dierence arising for the primary ecacy endpoint. The latter variable only assessed patients self-reported improvement in erectile function during sexual activity. Sildena®l treatment was well tolerated with no withdrawals due to study drug intolerance. All subjects in the sildena®l treatment group completed the 28-day study, with the exception of one who was lost to followup. During this part of the study only two subjects in the sildena®l group experienced adverse events (dyspepsia and chest infection) that were judged to be treatment-related. Adverse events in both parts of the study were predominantly mild in severity. No clinically signi®cant drug-related change in a laboratory test measurement was found during the study. These ®ndings are consistent with those of previous studies with sildena®l, in which the main adverse events were headache, vasodilation and dyspepsia. 8 The majority of our subjects received at least one concomitant medication during the study and there was no evidence of any adverse drug interactions between these drugs and sildena®l. Indeed, few clinically important drug interactions have been identi®ed with sildena®l during the phase III trial programme or in the several interaction studies that have been conducted in healthy volunteers. However, sildena®l and nitrates share a common metabolic pathway and should not be co-administered. While no signi®cant interaction has been demonstrated between sildena®l and oral anticoagulants or antiplatelet agents, it is recommended that sildena®l is administered with caution to patients with bleeding disorders or active peptic ulceration. Sildena®l is hepatically metabolised by cytochrome 3A4 and clearance is reduced when co-administered with inhibitors of this enzyme, such as cimetidine. Although sildena®l exerts mild vasodilatory eects, it can also be safely administered to patients receiving antihypertensive therapy. 12 Following the success of this pilot study, which has demonstrated the capability of treating ED in SCI men with a simple-to-take oral medication that exerts its eect only with sexual stimulation, a two-way crossover, double-blind, placebo-controlled, 6 week study is now underway. This trial will investigate¯exible dosing with up to 100 mg of sildena®l taken 1 h before sexual activity in a larger population of subjects recruited from European SCI units.
In conclusion, oral sildena®l taken not more than once daily is well tolerated and signi®cantly improves the quality of erections and satisfaction with sex life in men with ED caused by a SCI. The peripheral site of action of sildena®l aords the opportunity to amplify re¯exogenic erectile responses and increase the opportunity for a more appropriate and natural response during sexual activity in SCI men.
calculations was 60% in the sildena®l group and 25% in the placebo group. Based on this methodology the sample size was unknown prior to the start of the study; however, the expected number of subjects that was calculated was 39, with a maximum of 88.
A signi®cant dierence between the treatment groups in the response to global ecacy question A was seen after the third interim analysis, ie when 20 subjects had completed the study. However, at this time, an additional seven subjects had already been randomised to the study, six of whom had not yet completed and these subjects were allowed to continue.
Statistical methods
In Part I, the duration of erections 460% and 480% rigidity at the base and tip of the penis (four separate endpoints) were analyzed using non-parametric analysis as the data were highly skewed. For subjects who had more than one erection, the sum of the durations over the 90-min assessment period was calculated. The patient assessment of the best erectile response to PVS during each cross-over period was assessed using analysis of covariance (ANCOVA) appropriate for a cross-over design.
In Part II, the responses to global ecacy questions A and B were analyzed using logistic regression, including terms for treatment and centre eect. The proportion of successful attempts at sexual intercourse were analyzed using the non-parametric CochranMantel-Haenszel test of association, adjusted for centre eect. The weekly count of grade 3 or 4 erections from the diary and the responses to the patient sexual function and partner questionnaires were analyzed using ANCOVA, including terms for treatment, baseline eect (patient sexual function and partner questionnaires only), and centre eect. Both the ANCOVA and logistic analyses included the demographic covariates of age, smoking status, time since SCI, and site of lesion.
